0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Letters |

Response to Etanercept in Juvenile Idiopathic Arthritis—Reply

Marieke H. Otten, MD, MSc; Femke H. M. Prince, MD, PhD, MSc; Lisette W. A. van Suijlekom-Smit, MD, PhD, MSc
JAMA. 2012;307(11):1140-1141. doi:10.1001/jama.2012.329.
Text Size: A A A
Published online

Extract

In Reply: Dr Pang and colleagues bring up the importance of the differences in etiology and pathogenesis between systemic JIA compared with other JIA categories. As more insight into the pathogenesis of systemic JIA has been gained, systemic JIA has been considered by many as a different disease entity because of its clinical features and the involvement of different cytokines, such as interleukin 1 (IL-1), IL-6, and IL-18, in addition to tumor necrosis factor (TNF). While newer biological agents targeting the IL-1 and IL-6 cytokines seem important for systemic JIA, since 1999 many patients with systemic JIA have been treated successfully with etanercept, a TNF antagonist, in daily clinical care.1

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Letters

March 21, 2007
Thomas E. Finucane, MD
JAMA. 2007;297(11):1193-1195. doi:10.1001/jama.297.11.1193-b.
March 21, 2012
Hao Pang, MD; Xue-Hui Wu, MD; Jian-Zhong Xu, MD
JAMA. 2012;307(11):1140-1141. doi:10.1001/jama.2012.328.
CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();